Redmile Group, LLC Ovid Therapeutics Inc. Transaction History

Redmile Group, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$3.13 - $3.73 $127,309 - $151,714	-40,674 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$3.3 - $4.49 $268,210 - $364,929	-81,276 Reduced 66.65%	40,674 $159,000
Q3 2019 Nov 14, 2019	SELL	$1.76 - $3.51 $1.08 Million - $2.16 Million	-615,600 Reduced 83.47%	121,950 $395,000
Q4 2018 Feb 14, 2019	BUY	$2.42 - $6.6 $17,908 - $48,840	7,400 Added 1.01%	737,550 $1.79 Million
Q3 2018 Nov 14, 2018	BUY	$5.6 - $11.0 $3.41 Million - $6.69 Million	608,200 Added 498.73%	730,150 $4.14 Million
Q2 2018 Aug 14, 2018	SELL	$6.16 - $10.14 $238,810 - $393,107	-38,768 Reduced 24.12%	121,950 $951,000
Q1 2018 May 15, 2018	SELL	$6.53 - $9.82 $992,977 - $1.49 Million	-152,064 Reduced 48.62%	160,718 $0
Q4 2017 Feb 14, 2018	SELL	$6.12 - $12.31 $847,008 - $1.7 Million	-138,400 Reduced 30.67%	312,782 $3.09 Million
Q3 2017 Nov 14, 2017	BUY	$5.32 - $9.77 $2.4 Million - $4.41 Million	451,182	451,182 $3.77 Million

39M

37.4K

500

Ticker OVID
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,419,400
Market Cap $65.5M
Description
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment o...

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Redmile Group, LLC with notifications on news.